Collaborating scientists at the Karolinska Institute and at Stockholm University used a technology called in situ sequencing (ISS) to help reveal at the cellular level how lesions in multiple ...

Between 30 to 50 percent of people living with multiple sclerosis (MS) will experience memory problems but the cause is uncertain. Brain lesions are the hallmark imaging sign used to diagnose MS and ...

Brain lesions — areas of brain tissue that show damage from injury or disease — are the biomarker most widely used to determine multiple sclerosis disease progression. But an innovative new study led ...

"[These results] show that white matter lesions across all MS patients tend to injure the white matter depression network, which may create a vulnerability for depression in the MS population as a ...

BUFFALO, N.Y. – In recent years, researchers studying multiple sclerosis have concluded that white matter lesion volume in the brain, long considered the best way to monitor MS disease progression, ...

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) said its oral drug fenebrutinib met the main and secondary goals of a phase 2 trial by reducing brain lesions in adults with relapsing forms of multiple sclerosis ...

Between 30 to 50 percent of people living with multiple sclerosis (MS) will experience memory problems but the cause is uncertain. Brain lesions are the hallmark imaging sign used to diagnose MS and ...

The number of cortical lesions at baseline may indicate a patient's risk of developing secondary progressive multiple sclerosis (MS), according to new research. Cortical lesions also may be an early ...

Prospective tracking of "smoldering" chronic active lesions with notable darkened rims in people with multiple sclerosis (MS), previously only detectable upon autopsy, suggests the lesions are linked ...

"We plan to analyze these MRI structural measures longitudinally to determine if changes in brain volumes or lesion burden over time contribute to fatigue trajectories. More broadly, we might ...